1. Cancer Biology
Download icon

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies

  1. Ana Rita Pombo Antunes
  2. Isabelle Scheyltjens
  3. Johnny Duerinck
  4. Bart Neyns
  5. Kiavash Movahedi  Is a corresponding author
  6. Jo A Van Ginderachter  Is a corresponding author
  1. VIB Center for Inflammation Research, Belgium
  2. Vrije Universiteit Brussel, Belgium
  3. UZ Brussels, Belgium
Review Article
Cite this article as: eLife 2020;9:e52176 doi: 10.7554/eLife.52176
1 figure


Heterogeneity of the glioblastoma immune microenvironment and potential therapeutic targets.

Within glioblastoma tumors reside ontogenically distinct, immunoregulatory macrophages (Sall1+ tumor microglia, Sall1- monocyte-derived macrophages), immunosuppressive Treg (eg CCR8+) and dysfunctional T-cell populations (CTLA-4/PD-1hi). Not much is known about intratumoral DC subsets, although distinct DC populations are found in other brain regions, such as the dura mater (Van Hove et al., 2019). Glioblastoma also affects the phenotype of classical monocytes (Cl. Monocyte) in the periphery, which acquire an immunosuppressive (MDSC-like?) phenotype. Notably, the genetic make-up of the cancer cells (blue rectangle) and potentially also of the glioblastoma stem cells, affect the immune composition of the tumor, with for example a higher presence of lymphocytes in TCGA-MES tumors. Several potential therapeutic targets (CSF1R, SIRPa, CCR8, PD-1, CTLA-4), either already tested in the clinic or promising for the future, are highlighted.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)